Geneos Therapeutics — personalized DNA neoantigen vaccines (GT-30) delivered by electroporation, notably in liver cancer.
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer The Malaysian Reserve
Geneos Therapeutics initiated IMPACT31 (NCT07722741), a global multicenter Phase 2 randomized trial planning to enroll 90 patients with high-risk hepatocellular carcinoma who have undergone curative-intent resection, testing its personalized DNA immunotherapy GNOS-PV02 against active surveillance. The adjuvant design targets recurrence prevention in a post-surgical population, a setting with a cleaner regulatory path than advanced disease if it reads out. The company also appointed Julie Rosenberg, MD, a biopharma veteran with more than two decades of drug development experience, as Chief Medical Officer to drive the trial.
Geneos Therapeutics, Wistar, and collaborators translate personalized DNA vaccine technology into clinical outcome based on mistakes tumors make image: Dr. David Weiner, EVP of The Wistar Institute PHILADELPHIA — (Tuesday, April 30, 2024) — Hepatocellular carcinoma (H…
Summit organizers frame the field at an inflection point: Moderna and Merck have reported positive initial Phase 3 data for intismeran autogene in combination with Keytruda, putting the first regulatory approval of a personalized neoantigen cancer vaccine firmly within sight. The 3rd Annual Personalized Cancer Vaccine Summit (December 1-3, 2026) draws 80+ leaders from Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, and Transgene. The stated agenda — development, manufacturing, delivery, and market access — is a useful proxy for where the industry sees its next bottlenecks now that proof-of-concept is largely settled.
[RECRUITING · PHASE2 · Geneos Therapeutics] This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on p…
Geneos Therapeutics has launched a randomized, open-label Phase II study (NCT07722741) for GNOS-PV02, a personalized neoantigen DNA vaccine combined with plasmid-encoded IL-12 (INO-9012). The trial targets patients with high-risk hepatocellular carcinoma (HCC) who are disease-free post-resection, aiming to prevent recurrence. This marks a significant clinical step for Geneos in validating its DNA-based platform in a adjuvant setting.